Cargando…

Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

BACKGROUND: Current therapeutic options for atopic dermatitis (AD) are limited. Janus kinase (JAK) inhibitors may be viable alternatives. OBJECTIVES: To assess the efficacy and safety of JAK inhibitors for AD treatment. METHODS: We searched PubMed, Embase, the Cochrane Controlled Register of Trials,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chenyang, Sun, Xun, Zhao, Kun, Meng, Fanxiang, Li, Lin, Mu, Zhenzhen, Han, Xiuping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Atopic Dermatitis − Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393843/ https://www.ncbi.nlm.nih.gov/pubmed/34455413 http://dx.doi.org/10.1159/000518541

Ejemplares similares

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Atopic dermatitis epidemiology and unmet need in the United Kingdom
por: Cork, Michael J., et al.
Publicado: (2019)

Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology
por: Aoki, Valeria, et al.
Publicado: (2019)

Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year
por: Kennedy, Elizabeth A., et al.
Publicado: (2017)

Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity
por: Saunders, Sean P., et al.
Publicado: (2016)

Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis
por: Riethmuller, Christoph, et al.
Publicado: (2015)

Care pathways in atopic dermatitis: a retrospective population‐based cohort study
por: von Kobyletzki, L., et al.
Publicado: (2022)

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
por: Simpson, Eric L., et al.
Publicado: (2014)

The Skin and Nose Microbiome and Its Association with Filaggrin Gene Mutations in Pediatric Atopic Dermatitis
por: van Mierlo, Minke M.F., et al.
Publicado: (2022)

Raman profiles of the stratum corneum define 3 filaggrin genotype–determined atopic dermatitis endophenotypes
por: O'Regan, Gráinne M., et al.
Publicado: (2010)

Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis
por: Cole, Christian, et al.
Publicado: (2014)

Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects
por: Saunders, Sean P., et al.
Publicado: (2013)

Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy
por: Brough, Helen A., et al.
Publicado: (2015)

HautTief Multidisciplinary Educational Program for Patients with Psoriasis or Atopic Dermatitis: A Randomized Controlled Study
por: Sahin, Ugur, et al.
Publicado: (2022)

Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma
por: Andersen, Yuki M.F., et al.
Publicado: (2017)

Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year
por: Kelleher, Maeve, et al.
Publicado: (2015)

Non‐invasive transcriptomic analysis using mRNAs in skin surface lipids obtained from children with mild‐to‐moderate atopic dermatitis
por: Shima, K., et al.
Publicado: (2022)

Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency
por: Kezic, Sanja, et al.
Publicado: (2012)

Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis
por: Alkon, Natalia, et al.
Publicado: (2022)

A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis
por: Naeem, Aishath S., et al.
Publicado: (2017)

Atopic Dermatitis and Respiratory Allergy: What is the Link
por: Belgrave, Danielle C. M., et al.
Publicado: (2015)

Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series
por: Slodownik, Dan, et al.
Publicado: (2022)

Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin
por: McAleer, Maeve A., et al.
Publicado: (2015)

The Role of the Environment and Exposome in Atopic Dermatitis
por: Stefanovic, Nicholas, et al.
Publicado: (2021)

Atopic eczema in adulthood and mortality: UK population–based cohort study, 1998-2016
por: Silverwood, Richard J., et al.
Publicado: (2021)

Chromosome 11q13.5 variant associated with childhood eczema: An effect supplementary to filaggrin mutations
por: O'Regan, Gráinne M., et al.
Publicado: (2010)

Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus
por: Miajlovic, Helen, et al.
Publicado: (2010)

Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells
por: Leitch, Claire S., et al.
Publicado: (2016)

Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review
por: Su, Zheng, et al.
Publicado: (2023)

Manual de dermatitis por contacto/
por: Fregert, Sigfrid
Publicado: (1977)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Le, Michelle, et al.
Publicado: (2021)

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Singh, Rhea, et al.
Publicado: (2020)

Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis
por: Alves, Carlos, et al.
Publicado: (2023)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis
por: Chen, Qianyu, et al.
Publicado: (2023)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
por: Gooderham, Melinda J., et al.
Publicado: (2019)

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
por: SEDEH, Farnam B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cv4ju7h9fi89b7feajimmvmrs3